3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
4
Other hematologic neoplasm
1
Dermatologic
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
87
Lymphoma, Non-Hodgkin
21
Leukemia
18
Lymphoma, Follicular
17
Lymphoma, B-Cell, Marginal Zone
14
Lymphoma
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Lymphoma, Mantle-Cell
12
Lymphoma, Large B-Cell, Diffuse
12
Lymphoma, B-Cell
10
Recurrence
7
Leukemia, Myeloid, Acute
7
Hodgkin Disease
7
Waldenstrom Macroglobulinemia
6
Leukemia, B-Cell
6
Hematologic Neoplasms
6
Burkitt Lymphoma
6
Myelodysplastic Syndromes
5
Multiple Myeloma
5
Sezary Syndrome
4
Mycosis Fungoides
4
Leukemia, Hairy Cell
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms
3
Myeloproliferative Disorders
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, T-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Large-Cell, Anaplastic
3
Interventions
blinatumomab
4
fludarabine
3
Rituximab
3
Cyclophosphamide
3
ponatinib
2
ibrutinib
2
fludarabine phosphate
2
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Busulfan
2
Bone Marrow Transplantation
2
venetoclax
1
tetulomab tetraxetan lu-177
1
pomalidomide
1
obinutuzumab
1
durvalumab
1
dacetuzumab
1
amonafide
1
acalabrutinib
1
Tinzaparin
1
Lutetium-177
1
Lutetium
1
Lenalidomide
1
Imatinib Mesylate
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphatic Diseases
×
Bendamustine Hydrochloride
×
Other hematologic neoplasm
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts